These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 28629923)

  • 1. Immunogenicity and safety of a fully liquid DTaP-IPV-HB-PRP∼T hexavalent vaccine compared with the standard of care in infants in the Republic of Korea.
    Kim YK; Vidor E; Kim HM; Shin SM; Lee KY; Cha SH; Ma SH; Kim DH; Lee J; Park SE; Lee H; Kim JD; Kim KH; Kim KH; Kim JH;
    Vaccine; 2017 Jul; 35(32):4022-4028. PubMed ID: 28629923
    [No Abstract]   [Full Text] [Related]  

  • 2. A Randomized Controlled Study of a Fully Liquid DTaP-IPV-HB-PRP-T Hexavalent Vaccine for Primary and Booster Vaccinations of Healthy Infants and Toddlers in Latin America.
    López P; Arguedas Mohs A; Abdelnour Vásquez A; Consuelo-Miranda M; Feroldi E; Noriega F; Jordanov E; B Chir S; Zambrano B
    Pediatr Infect Dis J; 2017 Nov; 36(11):e272-e282. PubMed ID: 28719500
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Concomitant administration of a fully liquid, ready-to-use DTaP-IPV-HB-PRP-T hexavalent vaccine with a meningococcal serogroup C conjugate vaccine in infants.
    Vesikari T; Borrow R; Da Costa X; Richard P; Eymin C; Boisnard F; Lockhart S
    Vaccine; 2017 Jan; 35(3):452-458. PubMed ID: 27939054
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and immunogenicity of a hexavalent diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine at 2, 3, 4, and 12-14 months of age.
    Halperin SA; Tapiero B; Diaz-Mitoma F; Law BJ; Hoffenbach A; Zappacosta PS; Radley D; McCarson BJ; Martin JC; Brackett LE; Boslego JW; Hesley TM; Bhuyan PK; Silber JL
    Vaccine; 2009 Apr; 27(19):2540-7. PubMed ID: 19124057
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A fully liquid DTaP-IPV-Hep B-PRP-T hexavalent vaccine for primary and booster vaccination of healthy Mexican children.
    Aquino AG; Brito MG; Doniz CE; Herrera JF; Macias M; Zambrano B; Plennevaux E; Santos-Lima E
    Vaccine; 2012 Oct; 30(45):6492-500. PubMed ID: 22863658
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Phase III randomized, double-blind, clinical trial of an investigational hexavalent vaccine given at 2, 4, and 11-12 months.
    Silfverdal SA; Icardi G; Vesikari T; Flores SA; Pagnoni MF; Xu J; Liu GF; Stek JE; Boisnard F; Thomas S; Ziani E; Lee AW
    Vaccine; 2016 Jul; 34(33):3810-6. PubMed ID: 27288217
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunogenicity and safety of a new hexavalent vaccine (DTaP5-IPV-HB-Hib) administered in a mixed primary series schedule with a pentavalent vaccine (DTaP5-IPV-Hib).
    Martinón-Torres F; Boisnard F; Thomas S; Sadorge C; Borrow R;
    Vaccine; 2017 Jun; 35(30):3764-3772. PubMed ID: 28583305
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunogenicity and safety of primary and booster vaccination with 2 investigational formulations of diphtheria, tetanus and Haemophilus influenzae type b antigens in a hexavalent DTPa-HBV-IPV/Hib combination vaccine in comparison with the licensed Infanrix hexa.
    Vesikari T; Rivera L; Korhonen T; Ahonen A; Cheuvart B; Hezareh M; Janssens W; Mesaros N
    Hum Vaccin Immunother; 2017 Jul; 13(7):1505-1515. PubMed ID: 28340322
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Persistence of hepatitis B immune memory until 9-10 years of age following hepatitis B vaccination at birth and DTaP-IPV-HB-PRP∼T vaccination at 2, 4 and 6 months.
    Kosalaraksa P; Chokephaibulkit K; Benjaponpitak S; Pancharoen C; Chuenkitmongkol S; B'Chir S; Da Costa X; Vidor E
    Hum Vaccin Immunother; 2018 May; 14(5):1257-1265. PubMed ID: 29333947
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunogenicity and safety of an investigational hexavalent diphtheria-tetanus-acellular pertussis-inactivated poliovirus-hepatitis B-Haemophilus influenzae B conjugate combined vaccine in healthy 2-, 4-, and 6-month-old Argentinean infants.
    Tregnaghi MW; Zambrano B; Santos-Lima E
    Pediatr Infect Dis J; 2011 Jun; 30(6):e88-96. PubMed ID: 21372751
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and immunogenicity of a toddler dose following an infant series of a hexavalent diphtheria, tetanus, acellular pertussis, inactivated poliovirus, Haemophilus influenzae type b, hepatitis B vaccine administered concurrently or at separate visits with a heptavalent pneumococcal conjugate vaccine.
    Halperin SA; Tapiéro B; Dionne M; Meekison W; Diaz-Mitoma F; Zickler P; Rubin E; Embree J; Bhuyan P; Lee A; Li M; Tomovici A
    Pediatr Infect Dis J; 2014 Jan; 33(1):73-80. PubMed ID: 24346596
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and immunogenicity of a hexavalent vaccine administered at 2, 4 and 6 months of age with or without a heptavalent pneumococcal conjugate vaccine: a randomized, open-label study.
    Tapiéro B; Halperin SA; Dionne M; Meekison W; Diaz-Mitoma F; Zickler P; Rubin E; Embree J; Bhuyan P; Lee AW; Li M; Tomovici A
    Pediatr Infect Dis J; 2013 Jan; 32(1):54-61. PubMed ID: 23241989
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibody persistence after a primary series of a new DTaP-IPV-Hep B-PRP-T combined vaccine or separate DTaP-IPV//PRP-T and hepatitis B vaccines at 2, 4, and 6 months of age and the effect of a subsequent DTaP-IPV//PRP-T booster vaccination at 18 months of age in healthy Argentinean infants.
    Tregnaghi M; Zambrano B; Santos-Lima E
    Pediatr Infect Dis J; 2012 Jan; 31(1):e24-30. PubMed ID: 22157567
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenicity and safety of a combined diphtheria, tetanus, acellular pertussis, and inactivated poliovirus vaccine (DTaP-IPV) compared to separate administration of standalone DTaP and IPV vaccines: a randomized, controlled study in infants in the Republic of Korea.
    Lee SY; Hwang HS; Kim JH; Kim HH; Lee HS; Chung EH; Park SE; Ma SH; Chang JK; Guitton F; Ortiz E; Kang JH
    Vaccine; 2011 Feb; 29(8):1551-7. PubMed ID: 21215828
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunogenicity and safety of a pentavalent acellular pertussis combined vaccine including diphtheria, tetanus, inactivated poliovirus and conjugated Haemophilus Influenzae type b polysaccharide for primary vaccination at 2, 3, 4 or 3, 4, 5 months of age in infants in China.
    Li RC; Li FX; Li YP; Hou QM; Li CG; Li YN; Chen FS; Hu XZ; Su WB; Zhang SM; Fang HH; Ye Q; Zeng TD; Liu TX; Li XB; Huang YN; Deng ML; Zhang YP; Ortiz E
    Vaccine; 2011 Feb; 29(10):1913-20. PubMed ID: 21219984
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunogenicity and reactogenicity of two regimens of diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio and Haemophilus influenzae type b vaccines administered to infants primed at birth with hepatitis B vaccine.
    Cheng HK; Rajadurai VS; Amin Z; Sriram B; Yee MF; Han HH; Bock HL; Safary A
    Southeast Asian J Trop Med Public Health; 2004 Sep; 35(3):685-92. PubMed ID: 15689088
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibody persistence and booster vaccination of a fully liquid hexavalent vaccine coadministered with measles/mumps/rubella and varicella vaccines at 15-18 months of age in healthy South African infants.
    Madhi SA; Koen A; Cutland C; Groome M; Santos-Lima E
    Pediatr Infect Dis J; 2013 Aug; 32(8):889-97. PubMed ID: 23538523
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and immunogenicity of three different formulations of a liquid hexavalent diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine at 2, 4, 6 and 12-14 months of age.
    Diaz-Mitoma F; Halperin SA; Tapiero B; Hoffenbach A; Zappacosta PS; Radley D; Bradshaw S; Martin JC; Boslego JW; Hesley TM; Bhuyan PK; Silber JL
    Vaccine; 2011 Feb; 29(6):1324-31. PubMed ID: 21134456
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunogenicity and safety study of a new DTaP-IPV-Hep B-PRP-T combined vaccine compared to a licensed DTaP-IPV-Hep B//PRP-T comparator, both concomitantly administered with a 7-valent pneumococcal conjugate vaccine at 2, 4, and 6 months of age in Thai infants.
    Kosalaraksa P; Thisyakorn U; Benjaponpitak S; Chokephaibulkit K; Santos-Lima E
    Int J Infect Dis; 2011 Apr; 15(4):e249-56. PubMed ID: 21334243
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibody persistence at 18-20 months of age and safety and immunogenicity of a booster dose of a combined DTaP-IPV//PRP∼T vaccine compared to separate vaccines (DTaP, PRP∼T and IPV) following primary vaccination of healthy infants in the People's Republic of China.
    Li RC; Li FX; Li YP; Hou QM; Li CG; Li YN; Chen FS; Hu XZ; Su WB; Zhang SM; Fang HH; Ye Q; Zeng TD; Liu TX; Li XB; Huang YN; Deng ML; Zhang YP; Ortiz E
    Vaccine; 2011 Nov; 29(50):9337-44. PubMed ID: 22001281
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.